trial

Luteolin for the Treatment of People With Schizophrenia

NCTId NCT05204407
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 85 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2026-01-14
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
85 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2022-06-13
Primary completion
2026-01-14
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Luteolin

Sponsors

University of Maryland, Baltimore CountyLead Sponsor
University of California Riverside at C.I. Trials, Inc.-Inland EmpireCollaborator
Stanley Medical Research InstituteCollaborator

Investigators

1
Deanna Kelly, PharmDPrincipal Investigator

Sites

2 total
Los Angeles, United StatesBaltimore, United States

Facts & assertions

4 sourced
Enrollment
85
Phase
NA
Primary Completion Date
2026-01-14
Status
COMPLETED
relationships
The graph out of here
drug
Luteolin
drug
lead_sponsor
University of Maryland, Baltimore County
company
collaborator
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Deanna Kelly, PharmD
person